<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERGOLOID MESYLATE</span><br/>(er'goe-loid mess'i-late)<br/><span class="topboxtradename">Gerimal, </span><span class="topboxtradename">Hydergine, </span><span class="topboxtradename">Hydroloid G, </span><span class="topboxtradename">Niloric<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist (blocking agent, sympatholytic)</span>; <span class="classification">ergot alkaloid</span><br/><b>Prototype: </b>Ergotamine tartrate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg sublingual tablets; 0.5 mg, 1 mg tablets; 1 mg capsules; 1 mg/mL oral liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Combination of three hydrogenated derivatives of ergot alkaloids. Produces peripheral vasodilation primarily by central action
         and may cause slight reduction in BP and heart rate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reportedly relieves symptoms of cerebral arteriosclerosis, possibly by increasing cerebral metabolism with consequent increase
         in blood flow. Improvement may not be apparent until after 34 wk of therapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Senile dementia of Alzheimer type.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Acute or chronic psychosis; hypersensitivity to ergoloid. Safety during pregnancy (category C), lactation, or in children
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Acute intermittent porphyria.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Senile Dementia of Alzheimer Type</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg t.i.d.; doses up to 4.512 mg/d have been used<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Sublingual</span><br/><ul>
<li>Instruct patient to allow sublingual (SL) tablet to dissolve under tongue and not to drink, eat, or smoke while tablet is
            in place. Do not crush SL tablets.
         </li>
<li>Store in tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Mostly dose related. <span class="typehead">CV:</span> Orthostatic hypotension, dizziness or light-headedness, flushing, sinus bradycardia. <span class="typehead"> Special Senses:</span> Blurred vision, nasal stuffiness, increased nasopharyngeal secretions. <span class="typehead">GI:</span> Sublingual irritation, anorexia, stomach cramps, transient nausea and vomiting, heartburn. <span class="typehead">Skin:</span> Skin rash. <span class="typehead"> CNS:</span> Drowsiness, headache. <span class="typehead">Other:</span> Precipitation of acute intermittent porphyria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract; approximately 50% reaches systemic circulation. <span class="typehead"> Peak:</span>  1.53 h. <span class="typehead">Metabolism:</span> Undergoes rapid first-pass metabolism in liver. <span class="typehead">Elimination:</span> Primarily excreted in feces. <span class="typehead">Half-Life:</span> 212 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Establish baseline values of BP and pulse; check at regular intervals throughout therapy.</li>
<li>Report to physician sinus bradycardia (40 bpm); has been reported in patients receiving 1.5 mg doses. Pulse rate usually returns
            to normal within 2 d after drug is discontinued.
         </li>
<li>Withdraw drug permanently if marked bradycardia or hypotension occurs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Make position changes slowly, particularly from recumbent to upright posture, and move ankles and feet for a few minutes before
            walking.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>